THE ROLE OF GROWTH HORMONE IN CARDIOVASCULAR HEALTH

生长激素在心血管健康中的作用

• 批准号: 7605609
• 负责人: Jessica K Devin
• 金额: $ 2.01万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605609
• 关键词: Adult; Atherosclerosis; Cardiovascular system; Circadian Rhythms; Computer Retrieval of Information on Scientific Projects Database; Functional disorder; Funding; Future; Grant; Health; Individual; Inflammation; Institution; Investigation; Mediating; Pathogenesis; Patients; Plasma; Plasminogen Activator Inhibitor 1; Population; Proteins; Proteomics; Replacement Therapy; Research; Research Personnel; Resources; Role; Somatotropin; Somatropin; Source; Testing; United States National Institutes of Health; Venous; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The specific aims of our study will be to: 1. Determine the circadian rhythm of PAI-1 in the GHD population prior to and following appropriate replacement with hGH. We hypothesize that the levels of GH and PAI-1 will be inversely related within a normal individual. Additionally, since a GHD individual would lose their circadian secretion of GH, we hypothesize that their PAI-1 level would be chronically high while not on hGH replacement and chronically low once adequately replaced. 2. Evaluate the fibrinolytic potential of patients with GHD prior to and following replacement with hGH. We hypothesize that there will be a defective fibrinolytic response in GHD adults following the venous occlusion test, and that this effect will be abolished following adequate replacement therapy. 3. Evaluate endothelial dysfunction in patients with GHD prior to and following replacement with hGH. We hypothesize that flow-mediated dilation (FMD) will be less prominent in patients with GHD and we hypothesize that flow-mediated dilation will return to baseline following replacement therapy with hGH. 4. Compare, using proteomics, the plasma signature of proteins present in GHD individuals prior to and following replacement therapy with hGH. The absence or presence of different proteins present in the deficient versus the replaced state could only serve to raise further questions regarding the role of GH in inflammation and the pathogenesis of atherosclerosis that may warrant investigation in the future.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们研究的具体目标是： 1.在适当替代hGH之前和之后，确定GHD人群中派-1的昼夜节律。 我们推测GH和派-1水平在正常个体中呈负相关。此外，由于GHD个体将失去其GH的昼夜分泌，我们假设他们的派-1水平将在未进行hGH替代时长期高，并且一旦充分替代则长期低。 2.评价hGH替代治疗前后GHD患者的纤溶潜力。 我们推测，静脉闭塞试验后，GHD成人患者的纤溶反应存在缺陷，适当的替代治疗后，这种效应将被消除。 3.评价hGH替代治疗前后GHD患者的内皮功能障碍。 我们假设血流介导的扩张（FMD）在GHD患者中不太突出，我们假设在hGH替代治疗后血流介导的扩张将恢复至基线。 4.使用蛋白质组学比较hGH替代治疗前后GHD个体中存在的蛋白质的血浆特征。 缺乏或存在不同的蛋白质存在于与替代状态的不足，只能用来提出进一步的问题，GH在炎症和动脉粥样硬化的发病机制，可能需要在未来的调查中的作用。